Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, currently trading at 55.2 HKD with a transaction volume of 18.0035 million HKD, following the announcement of orphan drug designation for its dual-specific antibody, Viligene (Oparatuzumab, LBL-024) for the treatment of pulmonary neuroendocrine carcinoma by the European Commission [1] Group 1 - Valiant Pharmaceuticals-B's stock rose by 4.94% to 55.2 HKD as of the report [1] - The company reported a transaction volume of 18.0035 million HKD [1] - The European Commission granted orphan drug designation for Viligene on January 22, 2026, marking a significant milestone in its global development [1] Group 2 - This designation follows the previous orphan drug recognition by the U.S. Food and Drug Administration (FDA) [1] - The dual-specific antibody Viligene is aimed at treating pulmonary neuroendocrine carcinoma [1] - The orphan drug designation is a critical step in the drug's development process, enhancing its potential marketability and support [1]

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, reaching 55.2 HKD, following the announcement of orphan drug designation for its drug Valiant (Oparatuzumab, LBL-024) by the European Commission [1] Group 1 - On January 22, Valiant Pharmaceuticals-B announced that the European Commission granted orphan drug designation for its PD-L1/4-1BB bispecific antibody, Valiant, for the treatment of pulmonary neuroendocrine carcinoma [1] - This designation is a significant milestone, marking the second orphan drug designation for Valiant after receiving similar recognition from the U.S. Food and Drug Administration (FDA) [1] - The announcement reflects Valiant's progress in its global development efforts [1]

Core Viewpoint - The European Commission has granted orphan drug designation to Viligene (Opalizumab, LBL-024) for the treatment of extra-pulmonary neuroendocrine carcinoma, marking a significant milestone in its global development process after receiving similar recognition from the FDA [1][2]. Group 1 - The orphan drug designation is intended for medicines used to diagnose, prevent, or treat life-threatening or chronically debilitating diseases with a prevalence of less than 5 in 10,000 in the EU [2]. - The designation provides several key incentives, including scientific advice from the European Medicines Agency (EMA) on research design related to drug quality, benefits, and risks [2]. - The orphan drug status grants a 10-year market exclusivity period in the EU, during which no similar drugs for the same indication can be approved, ensuring protection even without patent coverage [2]. Group 2 - Additional benefits of orphan drug designation include fee reductions for regulatory guidance, marketing authorization applications, and post-marketing changes [2]. - Companies may also access funding from the European Commission, Horizon Europe, and other sources upon receiving orphan drug designation [2]. - Extra incentives are available for micro, small, and medium-sized enterprises, including regulatory, administrative, and procedural assistance, as well as fee reductions [2].

Core Viewpoint - The announcement by Vili Zhibo-B (09887) regarding the orphan drug designation for LBL-024 (Opalizumab) for the treatment of pulmonary neuroendocrine carcinoma marks a significant milestone in its global development process, following a similar designation from the FDA [1] Group 1 - The European Commission (EC) granted orphan drug designation for LBL-024 on January 9, 2026, which is the second such designation after receiving FDA recognition [1] - Orphan drugs are defined by the EC as those intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating conditions with a prevalence of less than 5 in 10,000 in the EU [2] Group 2 - The orphan drug designation provides several key incentives, including scientific advice from the European Medicines Agency (EMA) on various aspects of research design [2] - It grants a 10-year market exclusivity period in the EU from the date of marketing authorization, preventing other companies from approving similar drugs for the same indication during this time [2] - Additional benefits include fee reductions for regulatory processes and potential funding from the EC and Horizon Europe, as well as extra incentives for micro, small, and medium-sized enterprises [2]

Core Viewpoint - The company Valiant Biopharma-B (09887) has received Fast Track designation from the FDA for its PD-L1/4-1BB bispecific antibody, Valiant (Opatasumab, LBL-024), aimed at treating pulmonary neuroendocrine carcinoma, which accelerates the drug development process for serious conditions [1][2]. Group 1: Drug Development and Regulatory Milestones - Valiant is the first bispecific antibody targeting both PD-L1 and 4-1BB to reach the registration clinical stage for pulmonary neuroendocrine carcinoma [2]. - The Fast Track designation allows for more frequent regulatory interactions and the ability to submit a rolling New Drug Application (NDA) [1]. - The company has received Breakthrough Therapy Designation (BTD) from the NMPA for Valiant in treating advanced pulmonary neuroendocrine carcinoma, and Orphan Drug Designation (ODD) from the FDA for neuroendocrine carcinoma [2]. Group 2: Clinical Efficacy and Safety - In clinical trials in China, Valiant has shown promising efficacy signals and good safety profiles as both a monotherapy and in combination with chemotherapy for advanced pulmonary neuroendocrine carcinoma [2]. - The drug exhibits strong clinical activity potential in multiple indications, including non-small cell lung cancer, small cell lung cancer, and pulmonary neuroendocrine carcinoma [2]. - Valiant's design aims to overcome PD-1/L1 immune suppression and enhance T cell activation, indicating a broader cancer treatment potential compared to PD-1/L1 inhibitors [2]. Group 3: Broader Implications and Future Potential - 4-1BB as an agonist can reactivate exhausted T cells, making it suitable for treating "cold tumors" resistant to PD-1/PD-L1 therapies [3]. - Valiant has shown encouraging clinical signals in various cancers with unmet medical needs, including small cell lung cancer, cholangiocarcinoma, ovarian cancer, and triple-negative breast cancer [3]. - The drug is positioned to become a promising anti-tumor agent across a wide range of indications [3].